PMID- 15668900
OWN - NLM
STAT- MEDLINE
DCOM- 20050208
LR  - 20151119
IS  - 0046-8177 (Print)
IS  - 0046-8177 (Linking)
VI  - 35
IP  - 11
DP  - 2004 Nov
TI  - Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical 
      and genetic markers.
PG  - 1413-8
AB  - Anaplastic meningiomas (MIIIs) and meningeal hemangiopericytomas (HPCs) display 
      significant morphologic and immunohistochemical overlap, including occasional 
      cases of otherwise classic HPC with focal epithelial membrane antigen (EMA) 
      positivity. The availability of several new biomarkers prompted us to examine the 
      potential diagnostic roles of ancillary immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH) studies. From the archival university 
      neuropathology and consult files of 1 of the authors (A.P.), 19 meningeal HPCs 
      and 19 MIIIs were retrieved for further study. IHC was performed by using EMA, 
      CAM 5.2, CD99, Bcl-2, claudin-1 and Factor XIIIa (FXIIIa) antibodies. FISH was 
      performed with NF2, 4.1B (DAL-1), chromosome 1p32, and 14q32 probes. HPCs showed 
      strong CD99 (85% of cases), strong bcl-2 (86%), focal EMA (33%), focal claudin-1 
      (13%), and scattered individual cell FXIIIa (100%) positivity. MIIIs showed 
      strong EMA (89%), strong claudin-1 (54%), weak or focal CD99 (15%), weak or focal 
      bcl-2 (31%), and individual cell FXIIIa (84%) positivity. Focal CAM 5.2 
      expression was seen in 26% of HPCs and 15% of MIIIs. Deletions were extremely 
      common in MIIIs: 1p (94%), 14q (67%), NF2 (100%), and 4.1B (67%). HPCs showed no 
      14q or 4.1B deletions, with 1 case each of 1p and NF2 deletions (6%). The 
      sensitivities and specificities of the 3 most useful IHC markers (EMA, CD99, 
      bcl-2) were 85%-89% and 67%-84%, respectively. The sensitivity and specificity of 
      claudin-1 for MIII were 54% and 86%, respectively. The specificity and positive 
      predictive value of combined CD99 and bcl-2 expression for the diagnosis of HPC 
      was 95%. The sensitivities of individual genetic markers were 67%-100%, with 
      specificities of 94%-100%. Our 3 conclusions were as follows: (1) EMA, CD99, 
      bcl-2, and claudin-1 IHC and 1p, 14q, NF2, and 4.1B FISH are particularly useful 
      for distinguishing anaplastic meningiomas from meningeal HPCs. (2) Focal EMA 
      expression does not preclude a diagnosis of HPC. (3) The characteristic FXIIIa 
      staining pattern reported for HPC also is encountered frequently in anaplastic 
      meningiomas and therefore is nonspecific in this diagnostic setting.
FAU - Rajaram, Veena
AU  - Rajaram V
AD  - Department of Pathology, Washington University School of Medicine, St. Louis, MO 
      63110-1093, USA.
FAU - Brat, Daniel J
AU  - Brat DJ
FAU - Perry, Arie
AU  - Perry A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - DNA, Neoplasm/analysis
MH  - Genetic Markers/*genetics
MH  - Hemangiopericytoma/genetics/metabolism/*pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Meningeal Neoplasms/genetics/metabolism/*pathology
MH  - Meningioma/genetics/metabolism/*pathology
MH  - Sensitivity and Specificity
EDAT- 2005/01/26 09:00
MHDA- 2005/02/09 09:00
CRDT- 2005/01/26 09:00
PHST- 2005/01/26 09:00 [pubmed]
PHST- 2005/02/09 09:00 [medline]
PHST- 2005/01/26 09:00 [entrez]
AID - S0046817704004332 [pii]
AID - 10.1016/j.humpath.2004.07.017 [doi]
PST - ppublish
SO  - Hum Pathol. 2004 Nov;35(11):1413-8. doi: 10.1016/j.humpath.2004.07.017.